BriaCell Therapeutics Corp. (BCTXW)

CA — Healthcare Sector
Peers: BCTX  GOVXW  IMTXW  ATNFW  RVPHW 

Automate Your Wheel Strategy on BCTXW

With Tiblio's Option Bot, you can configure your own wheel strategy including BCTXW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BCTXW
  • Rev/Share 0.0
  • Book/Share 3.1967
  • PB 0.0117
  • Debt/Equity 0.0
  • CurrentRatio 3.4141
  • ROIC -1.9271

 

  • MktCap 263569.0
  • FreeCF/Share -6.4446
  • PFCF -0.0109
  • PE -0.0075
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -4.3972

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About BriaCell Therapeutics Corp. (BCTXW)

  • IPO Date
  • Website https://briacell.com
  • Industry Biotechnology
  • CEO William V. Williams FCPA,
  • Employees 16
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.